Evidence for Mesenchymal—Epithelial Transition Associated with Mouse Hepatic Stem Cell Differentiation

Bin Li*, Yun-Wen Zheng, Yuuki Sano, Hideki Taniguchi*

Department of Regenerative Medicine, Yokohama City University Graduate School of Medicine, Yokohama, Japan

Abstract
Mesenchymal—epithelial transition events are related to embryonic development, tissue construction, and wound healing. Stem cells are involved in all of these processes, at least in part. However, the direct evidence of mesenchymal—epithelial transition associated with stem cells is unclear. To determine whether mesenchymal—epithelial transition occurs in liver development and/or the differentiation process of hepatic stem cells in vitro, we analyzed a variety of murine liver tissues from embryonic day 11.5 to adults and the colonies derived from hepatic stem/progenitor cells isolated with flow cytometry. The results of gene expression, immunohistochemistry and Western blot showed that as liver develops, the expression of epithelial markers such as Cytokeratin18 and E-cadherin increase, while expression of mesenchymal markers such as vimentin and N-cadherin decreased. On the other hand, in freshly isolated hepatic stem cells, the majority of cells (65.0%) co-express epithelial and mesenchymal markers; this proportion is significantly higher than observed in hematopoietic cells, non-hematopoietic cells and non-stem cell fractions. Likewise, in stem cell-derived colonies cultured over time, upregulation of epithelial genes (Cytokeratin-18 and E-cadherin) occurred simultaneously with downregulation of mesenchymal genes (vimentin and Snail1). Furthermore, in the fetal liver, vimentin-positive cells in the non-hematopoietic fraction had distinct proliferative activity and expressed early the hepatic lineage marker alpha-fetoprotein.

Conclusion: Hepatic stem cells co-express mesenchymal and epithelial markers; the mesenchymal—epithelial transition occurred in both liver development and differentiation of hepatic stem/progenitor cells in vitro. Besides as a mesenchymal marker, vimentin is a novel indicator for cell proliferative activity and undifferentiated status in liver cells.

Introduction
Mesenchymal—epithelial transition (MET) events are defined as those in which mesenchymal cells lose their motile, migratory properties and acquire cell polarity and adhesion to epithelia. MET and the reverse process, epithelial mesenchymal transition (EMT), both occur in normal tissue, including gastrulating and regenerating tissue, as well as abnormal tissues of fibrotic organs or tumors [1,2]. Thus, it is necessary to reveal the relationship between EMT/MET and stem cells. Indeed, EMT drives mammary epithelial cells to de-differentiate into mammary stem cells and cancer stem cells which are mesenchymal-like [3]. Moreover, induced pluripotent stem cells (iPSCs) are derived from mouse embryonic fibroblasts (MEF) by MET at the early stage of reprogramming [4–6]. These results suggest the possibility that MET is associated with stem cell activities.

Recent work reported that rat hepatic oval cells (hepatic progenitors) express mesenchymal markers; this result indicated but not fully confirmed that MET existed in the process of hepatic progenitor cell differentiation [7]. On the other hand, hepatocytes, cholangiocytes and liver are known to undergo EMT under sophisticated regulation [8–12]. Furthermore, according to the pathological progression from normal liver to hepatic cirrhosis and then to hepatic carcinoma, EMT may be associated [8,13–15]. Therefore, MET in hepatic stem cells is important to multiple processes, including liver development, regeneration, and chronic liver injury.

In order to identify EMT/MET, vimentin is widely applied as a mesenchymal indicator [1,3,16–19]. Vimentin is an intermediate filament protein functionally involved in maintaining the structure of mesenchymal cells [20]. In addition to serving as a marker in EMT/MET, vimentin plays a versatile role in cancer cell motility. In prostate cancer cells, for example, vimentin links the motility and un-differentiated state of cells [21]. Notwithstanding, in breast cancer, vimentin mRNA expression is related to mesenchymal cell shape and motility [22]. In normal tissue injury, depletion of vimentin delays wound healing by mesenchymal fibroblasts trans-differentiating into epithelia [23]. Little is known about the relationship between vimentin expression and normal cell activation.

To address these questions, we investigated the mesenchymal characteristics of fetal liver cells and observed MET in developing mouse liver. Furthermore, based on our previous work [24], we isolated hepatic stem cells with flow cytometry in order to study
MET in stem cell differentiation. Importantly, we revealed that vimentin is associated with proliferative activity in liver cells.

Results

Mesenchymal—epithelial transition is a spontaneous process involved in mouse liver development

To investigate mesenchymal-epithelial transition in liver development, we analyzed the phenotype of cells and MET molecules in developing and adult mouse livers (Figure 1). ED11.5 liver cells are mesenchymal-like with lacking cell—cell connections (Figure 1A). As development proceeds, from ED11.5 to adult mouse, liver cells exhibited the change of cell shape from spindle to polygon, with larger size and tighter intercellular connections (Figure 1A). Moreover, an expansion of epithelial markers CK8/18 (Figure 1B and 1D; Table 1) and ZO-1 (Figure S1) but the reduction of vimentin through liver development were found (Figure 1B and 1D; Table 1). Similarly, an increasing of E-cadherin while decreasing of N-cadherin levels were observed (Figure 1C). N- and E-cadherin co-expressing cells were not found in adult liver (Figure 1C), demonstrating that not all the hepatocytes but cells around the central vein express N-cadherin, in consistent with the previous study [25]. Vimentin-positive cells in adult liver are only located near the portal vein, showing that blood vessel comprises these cells (Figure 1B; Figure S1). Statistically, in ED11.5 and ED13.5 liver, most non-hematopoietic cells are both epithelial and mesenchymal (CK8/18+ ’vimentin’) (Figure 1B), at a rate of 68.3±16.3% and 37.0±29.8%, respectively (Figure 1D; Table 1), in contrast to those of 25.8±7.1% in ED17.5 and 6.0±5.2% in adult liver (Figure 1B and 1D; Table 1). These versatile results provide evidence that mesenchymal and epithelial co-expressing cells decreased with the development stages of mouse liver.

After removing the hematopoietic cells, adult mouse liver showed a significant increasing of mRNAs encoding epithelial genes CK18 and E-cadherin by 107.8-fold and 8.5-fold, respectively, but remarkable reducing levels of vimentin, Snail1 and Twist1 gene by 9.4-fold, 3.7-fold, and 16.5-fold, respectively, to ED11.5 liver (Figure 2A). Similarly, CK8/18 protein was upregulated from ED11.5 to adult liver with a downregulation of vimentin protein (Figure 2B). These results indicate that MET naturally occurs over the course of mouse liver development.

Hepatic stem cells isolated from fetal liver co-express both epithelial and mesenchymal markers

After confirming that MET occurs in the developing mouse liver, we attempted to uncover the relationship between MET and hepatic stem cells, which are related to liver development. In this work we sorted mouse hepatic stem cells from ED13.5 mouse liver; these stem cells can form colonies in vitro and reconstruct liver in vivo, consistent with previous reports [24]. Using this method, we separated mouse embryonic liver cells into four fractions: CD45+TER119+ cells (hematopoietic cells), CD45+TER119+ cells (non-hematopoietic cells), c-Kit+CD49f+CD29+CD45+TER119+ cells, and c-Kit+CD49f+/lowCD29+CD45+TER119+ cells, which we considered to be the fetal liver stem cell fraction (Figure 3A). To figure out which fraction of cells expressed the epithelial and/or mesenchymal characteristics, we stained these cells for CK8/18 and vimentin using the Cytospin. As anticipated, of the 4 sorted cell fractions, the stem cells had the highest percentage (65.0%) of CK8/18 and vimentin double positive; this level was 43.3-fold higher than for hematopoietic cells (1.5%), 8.8-fold higher than non-hematopoietic cells (7.4%), and 59.1-fold higher than c-Kit+CD49f+/low-CD29+CD45+TER119+ cells (1.1%) (Figure 3B and 3C). Thus, the CK8/18 and vimentin double-positive population are mainly found in the stem cell fraction, which is significantly different from other cell fractions.

Mesenchymal-epithelial transition occurs in stem cell-derived colonies

To determine whether the mesenchymal and epithelial hepatic stem cells could experience MET events during stem cell differentiation, we cultured isolated stem cells for clonal colony assay and gene expression. Colonies on culture day 21 showed more expanded staining for epithelial markers albumin, CK8/18, CK7, ZO-1 and E-cadherin but less vimentin and N-cadherin than cells on day 0 (Figure 4 and Figure S3). Moreover, co-expression of CK8/18 and CK7 was detected in stem cell-derived colonies (Figure S3B), indicating biliary differentiation of CK18-expressing cells. Even on day 21, there are still cells double positive for albumin and CK7 (Figure S3D), meaning that they have hepatocyte and bile duct dual potential.

To further characterize MET in stem cell differentiation, we performed the quantitative assay for the dynamic changes of E-cadherin and vimentin, CK8/18 and vimentin expressions in stem cell-derived colonies in culture (Figure 5). Notably, the frequency of mesenchymal (vimentin+ cells) decreased from 84.0% on day 0 of culture to 48.3% on day 7 and 9.2% on day 21 (Figure 5A). In contrast, epithelial (E-cadherin+) cell frequency increased from day 0 (38.3%) to day 21 (98.1%); and CK8/18 positive cell proportion increased significantly, from 83.0% on day 0 to 100% on both day 7 and day 21, respectively (Figure 5A). Of these cells, the relative quantity of vimentin and E-cadherin co-expressing cells decreased from day 0 (77.9%) to day 7 (41.3%) and day 21 (10.3%); similarly, vimentin and CK8/18 double-positive cells decreased profoundly from day 0 (71.3%) to day 7 (48.3%) and day 21 (9.2%) (Figure 5A) (P<0.05). Furthermore, the albumin+ hepatocytes were all CK8/18 positive; these cells were first observed on day 7 (9.0%), and increased by day 21 (65.0%) (Figure 5A). Additionally, the differentiated hepatic cells (CK18+ and albumin+) in each colony are surrounded by the mesenchymal-like cells (CK18+ and Vimentin+) in the periphery of the colony (Figure 5), suggesting that centrally located cells undergo MET and become differentiated earlier than those in peripheral sites.

Relative gene expression measurements in stem cell-derived colonies confirmed and extended the results of immunocytochemistry, demonstrating upregulation of E-cadherin and CK18, but downregulation of vimentin, Snail1 and Twist1 (Figure 5B). Both CK18 and E-cadherin (Cdh1) gene expression increased significantly from day 0 to day 7 (10.3-fold for CK18 and 1.7-fold for E-cadherin) and from day 0 to day 21 (1.6-fold for CK18 and 3.2-fold for E-cadherin) while vimentin and Snail1 except Twist1 demonstrated downward trend in expression between day 0 and day 21 (1.9-fold for vimentin and 4.3-fold for Snail1) (Figure 5B). From the results of the colony assay and gene expression
Figure 1. Mesenchymal-epithelial transition occurs in developing mouse liver. (A) Phenotype changes of liver cells according to development stages. Representative images showed hematoxylin/eosin staining of livers from C57BL/6J mice at E11.5, 13.5 and 17.5 and 8 weeks (Adult) after birth. Right panels showed the magnified pictures. (B) Immunofluorescence for simultaneous detection of CK8/18 (epithelial) and vimentin (mesenchymal); (C) E-cadherin (epithelial) and N-cadherin (mesenchymal) in livers from mice in (A). Arrows in (B) showed the CK8/18 and vimentin overlapping cells. (D) The ratio for CK8/18 and/or vimentin expressing non-hematopoietic liver cells from mice in indicated development stages. Quantitative analyses were based on immunofluorescence staining. These images showed gain of epithelial characters and loss of mesenchymal characters within mouse liver development. Vim: vimentin. E: embryonic day. BV: Blood vessel. PV: Portal vein. Scale bars = 100 μm. doi:10.1371/journal.pone.0017092.g001
that in mouse liver of ED11.5 and ED13.5, hepatoblasts have been reported to be vimentin-positive mesenchymal fetal liver cells. As shown in Figure 6A, frequencies of AFP-positive liver cells were both very high at ED11.5 and ED17.5 (100%) comparing with that at ED13.5 (95.7%). Despite the decrease in the proportion of Vimentin-positive cells, the number of AFP-positive mesenchymal cells remains high at ED13.5 (95.7%) and even higher at ED17.5 (100%) in vivo. This indicates that vimentin is related to cell activation. Indeed, vimentin appears to be related to the activation of mesenchymal cells for proliferation. In our AFP/vimentin and BrdU/vimentin co-staining experiments, we reveal that the AFP-expressing liver cells are mesenchymal; furthermore, these cells are in a highly proliferative state. These results suggest that besides as a marker of mesenchymal tissue, vimentin has a novel role in connection with AFP expression.

**Table 1. Dynamic expression of hepatic cell types in liver development.**

|            | E11.5 | E13.5 | E17.5 | Adult |
|------------|-------|-------|-------|-------|
| Vim+       | 69.1±19.1^c | 40.9±7.9^c | 24.9±15.0 | 6.0±5.5 |
| CK8/18+    | 73.8±24.4 | 89.7±8.9 | 72.5±19.0 | 100    |
| AFP+       | 71.4±6.1 | 69.9±1.1 | 18.7±2.1^c | 0^c    |
| BrdU+      | 88.1±4.9^c | 42.9±3.9^c | 37.1±2.9 | 0.4±0.4^c |
| Vim+CK8/18+| 68.3±21.0^c | 39.1±18.9 | 25.8±7.1^c | 6.0±3.2^c |
| Vim+AFP+   | 69.1±6.4^c | 39.6±5.5^c | 17.5±1.8^c | 0^w    |
| Vim+BrdU+  | 69.1±6.3^c | 40.9±3.2^c | 24.9±4.7 | 6.0±3.2^c |
| Vim+       | 0.8±1.4 | 1.9±2.6 | 0 | 0 |
| Vim+CK8/18+| 5.5±7.1^c | 52.6±24.5 | 46.7±12.8 | 94.0±3.2^c |
| Vim+AFP+   | 6.9±4.3 | 30.3±8.6^c | 1.2±0.7^c | 0^c    |
| Vim+BrdU+  | 20.5±4.8 | 2.1±2.1 | 0.3±0.3 | 94.0±2.3^c |

dFour-group comparisons are labeled with *(p<0.05) and **(p<0.01). Two-group comparisons are labeled with the same alphabet (p<0.05) and b, c, d or e (p<0.01).

**Discussion**

Different stem cells, including hepatic stem cells, have mesenchymal characteristics

In this study, we confirmed that MET occurs during liver development between ED11.5 and adulthood in the mouse. Furthermore, by using fluorescence-activated cell sorting, we obtained evidence that hepatic stem cells, isolated from fetal liver, spontaneously experience MET during the differentiation into hepatocytes and biliary cells in vitro. Importantly, distinct from other cells isolated from fetal liver, hepatic stem cells have both epithelial and mesenchymal characteristics.

Consistent with our results, stem cells derived from different sources express mesenchymal characteristics. For example, stem cells in epithelial tissue, e.g., mammary stem cells, have been confirmed as mesenchymal-like [3,27]. This has also been confirmed in mesenchymal tissue, e.g., muscle stem cells and neural stem cells [28–30]. Moreover, embryonic stem cells also have a mesenchymal phenotype in the gastrulating embryo [31]. Furthermore, cancer-initiating cells or cancer stem cells in invasive tumors — e.g., intestine cancer stem cells [32], mammary cancer stem cells [3] and prostate cancer stem cells [33] — also have mesenchymal features. The results reported here may indicate that mesenchymal capability is necessary for stem cells derived from various sources to easily proliferate, loosen cell–cell connection, migrate and differentiate.

**Cell activation is associated with vimentin expression**

By detecting cells in S phase, BrdU staining can identify proliferative cells. In our AFP/vimentin and BrdU/vimentin co-staining experiments, we reveal that the AFP-expressing liver cells are mesenchymal; furthermore, these cells are in a highly proliferative state. These results suggest that besides as a marker of normal and abnormal mesenchymal cells [2,34,35], vimentin has a novel role in connection with AFP expression. Indeed, vimentin appears to be related to the activation of mesenchymal cells; for example, in vimentin-deficient mice, the motility and migration of fibroblasts are impaired [23]. In another report, vimentin-deficient cells exhibited decreased stiffness as well as decreased DNA synthesis [36]. More recently, vimentin has been regarded as mesenchymal cell marker in cancer-related EMT; drugs that target cancer cell growth also induce vimentin degradation in cancer cells [37]. These results support our finding that vimentin is related to cell activation in cancer as well as in normal tissue.

In addition to being associated with migration and proliferation of mesenchymal cells, vimentin is an indicator of cell morphology transformation or cytoskeleton reorganization [38,39]. In mouse embryonic gastrulation, vimentin increases in fibroblasts that delaminate through the primitive streak to become mesoderm [23,40,41], indicating that vimentin plays a role in cell transformation and tissue construction. Moreover, vimentin is closely related to loss of polarity of the plasma membrane in fiber cells [42], cell adhesion and polarization are associated with decreasing vimentin [43]. Furthermore, in metastatic cancer, epithelial cancer cells experience EMT concomitant with upregulation of vimentin as they dissociate from primary tumors, transform into mesenchyme, and migrate. These mesen-
Chymal cells then undergo MET concomitant with downregulation of vimentin at metastasis sites [3,16,44–46]. Interestingly, it is reported that cytoplasmic vimentin and keratin5/14 share a similar coil structure, though the function of this similarity is not clear [47], suggesting the possibility of a vimentin-to-keratin transition within the same cell, consistent with our observations of MET. The reorganization of vimentin molecular structure in the cytoplasm may explain the plasticity of stem cells and the transformation of mesenchymal cells into epithelial cells.

Although the link between stem cells and vimentin-positive cells in fetal liver has not been completely elucidated, we suggest that vimentin is a critical indicator for activated cells experiencing MET. Accordingly, because of the elastic state of stem cells, our results provide a hint that MET in stem cells indicates rearrangement of cytoskeleton as well. During the process of inactivating mesenchymal cells or the developing fetal liver, the number of vimentin-positive cells decreased (Figures 6 and 7).

Mesenchymal epithelial transition generates cell inactivation

In this study of MET, the adult liver expressed very low rate of vimentin, AFP and BrdU positive, suggesting that adult liver cells are in quiescent state. Based on the preceding statements, it can be inferred that MET drives stem cells into a quiescent state, whereas EMT is associated with reactivation or reprogramming of epithelial cells [3,45] (Figure 7). MET is also involved in other cell inactivation, for example, in wound healing, activated fibroblasts lose cell polarity, migrate into the wound site and differentiate into keratinocytes [23], a process driven by MET. During metastasis tumor invasion, epithelial tumor cells become mesenchymal-like and disassociate from the primary tumor, indicating that epithelial cell activation and proliferation [17] are driven by EMT. Subsequently, those de-differentiated mesenchymal cells colonize and differentiate into secondary carcinomas [17]. Comparing with invasive sites, the central area of many metastases showed reduced expression of nuclear β-catenin [48], indicating the inactivated state of the MET driven cells. Take together, it is suggested that in stem cell differentiation, wound healing and malignant tumor [32], MET process is related with cells changing from mesenchymal, de-polarized, proliferative and migrating state, to epithelial, polarized, differentiated, adhesive and inactivation state.

Mesenchymal epithelial transition in hepatic stem cell reflects a natural process in vitro

There is still some controversy about the relationship between the tissue microenvironments and EMT. One group claimed that cytokines such as EGF and HGF in cell culture can induce...
epithelial cells' transformation into mesenchymal-like cells [49]. In addition, other findings in pancreatic cells suggest that EMT is not involved in the origin of pancreatic mesenchymal stem cells (MSCs) [50]. In their report [50], EMT depended on the culture condition, and some of the vimentin single-positive cells are directly derived from the mesenchymal cells which are not experiencing EMT. Whether MET is influenced by these microenvironments is still unknown. In contrast, on one hand, we confirmed that MET occurs during mouse liver development both in vivo and in vitro (Figures 1, 2, 3, 4, 5). On the other hand, in stem cell colonies, the frequency of vimentin-positive cells decreased over the course of time in culture, and vimentin-positive but CD8/18-negative cells disappeared after day 7 (Figures 4 and 5A). These dynamic transitions indicate that the vimentin-positive mesenchymal cells differentiated into epithelial cells. Additionally, we found that differentiated hepatocytes (albumin-positive) are derived from CD8/18- and vimentin-positive hepatocytes (Figures 4 and 5A), demonstrating that MET occurs naturally in stem cell differentiation.

Conclusion
In summary, from the view of MET in this study, our results confirm the concept that MET is a normal process associated with stem cell differentiation and liver development. This may offer the promise of specifying the hepatic stem cells in liver regeneration and chronic liver injury, in which MET/EMT are involved. More importantly, to our knowledge, direct evidence shows that the addition to serving as a marker for mesenchymal cells, vimentin can also reveal cell activation and proliferation state. These results provide further insights that will help to elucidate the effects of vimentin in hepatic stem cell differentiation and progression of liver pathology.

Materials and Methods

Animals and cell preparation
C57BL/6j mice at embryonic days (ED) 11.5, 13.5, 17.5 and 8 weeks (Adult) after birth were purchased from Japan SLC (Tokyo, Japan). All animal experimentation was conducted in accordance with the Guidelines for Proper Conduct of Animal Experiments (Science Council of Japan), and all protocols were approved by institutional review board of Animal Research Center, Yokohama City University School of Medicine (09-48). For in vivo assays, C57BL/6j mouse livers from different developmental stages were embedded in OCT compound (Sakura Finetek, Japan). For immunofluorescence assays, Cryostat liver tissue sections were fixed with 4% paraformaldehyde (PFA) at 4°C for 5 min. For in vitro assays, C57BL/6j mouse livers from different development stages were embedded in Tissue-Tek® OCT compound (Matsunami glass, Japan). For immunofluorescence assays, Mouse primary antibodies and secondary antibodies were as described in Table S1. After final washing, cells were nuclei were stained blue with DAPI and viewed with a ZEISS Axio Imager.M1 microscope.

Histology and immunofluorescence
Tissues were fixed with 10% neutral formalin and embedded in paraffin. Histological 3-μm-thick serial cross sections were cut at 50-μm intervals and stained with hematoxylin and eosin. Cytosin samples were sorted on MAS coated glass slides (Matsunami glass, Japan), followed by centrifugation at 2000rpm, 4°C for 5 min. For in vivo assays, C57BL/6j mouse livers from different developmental stages were embedded in Tissue-Tek® OCT compound (Sakura Finetek, Japan). For immunofluorescence assays, Cytosin, cultured cells and cryostat liver tissue sections were fixed with 2% Paraformaldehyde (PFA) at 4°C for 20 minutes, and washed in PBS including 0.05% Tween 20 (Wako). Nonspecific binding was blocked with 10% nonimmune serum of a species from which the secondary antibody had been obtained. Samples were incubated with primary antibodies and secondary antibodies as described in Table S1. After final washing, cells were nuclei were stained blue with DAPI and viewed with a ZEISS Axio Imager.M1 microscope.

RNA isolation and Real-time PCR
Liver cells were treated as described above. Non-hematopoietic cells were collected after the removal of CD45~TER119~ labeled hematopoietic cells by flow cytometry. Total RNA was isolated with ISOGEN (Nippon gene, Tokyo, Japan), treated with DNaseI (Invitrogen, Carlsbad, CA) to get rid of genome DNA and complementary DNA (cDNA) was synthesized using the SuperScriptIII Reverse Transcriptase (Invitrogen), as described [24]. Quantitative reverse transcript PCR analysis was performed using the ABI PRISM7700 real-time PCR system (Applied Biosystems, Foster city, CA). Expression levels were normalized to that of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). TaqMan PCR probes (Applied Biosystems) are listed in Table S2.
Western blotting

Non-hematopoietic liver cells (CD45<sup>-</sup>TER119<sup>-</sup>) were isolated with IMag Streptavidin Particles Plus (BD Biosciences, San Jose, CA) under manufacture’s instructions. Cells were lysed in the presence of 50 mM Tris, pH 7.5, 150 mM NaCl, 0.1% SDS, 0.5% Deoxycholic acid sodium salt and 1% NP-40 on ice. Thirty micrograms of total protein from each sample was fractionated on a 10% Acrylamide Gel and transferred to PVDF membranes.

Figure 4. Mesenchymal—epithelial transition occurred in stem cell-derived colonies during culture. Immunofluorescence for stem cells and stem cell-derived colonies at indicated culture days. (A) CK8/18 and vimentin transition accompanied with hepatic differentiation of stem cells into albumin positive cells; (B) E-cadherin and N-cadherin, vimentin transition accompanied with hepatic differentiation of stem cells. Scale bars = 100 μm.
doi:10.1371/journal.pone.0017092.g004
Figure 5. *In vitro* quantitative assay for mesenchymal–epithelial transition of stem cell-derived colonies. (A) Quantification of immunofluorescence in cultured stem cells on day 0 and stem cell derived colonies on days 7 and 21. Upper panel, E-cadherin and vimentin expressing cell assay (dashed regions indicate double-negative cells); lower panel, CK8/18, vimentin and albumin assay. Graph showed quantification of three independent experiments. (B) Relative mRNA expressions in cultured stem cells and stem cell derived colonies. It showed up-regulation of epithelial genes, Cdh1 (E-cadherin) and CK18, and down-regulation of mesenchymal genes, vimentin, Snail1 and Twist1 during stem cell differentiation according to the passing by of culture time. Error bars represent standard errors in three independent experiments. **P<0.01. Alb: albumin. E-cad: E-cadherin.

doi:10.1371/journal.pone.0017092.g005
Figure 6. Vimentin-positive mesenchymal fetal liver cells are highly proliferative in vivo. (A) Representative images of dual immunofluorescence of AFP and vimentin; (B) BrdU and vimentin in mice livers at different developmental stages. AFP and BrdU expressions decreased accompanied with vimentin reduction. (C) and (D) represented the relative quantitative assay of non-hematopoietic cells in (A) and (B) respectively. These results showed that AFP positive liver cells also expressed vimentin, and the vimentin+ cells are highly proliferative (BrdU+). Scale bars = 100 μm.
doi:10.1371/journal.pone.0017092.g006
Blots were subjected to anti-vimentin (Sigma, St Louis, MO), anti-CK8/18 (PROGEN, Germany) and anti-β-actin (Cell Signaling, Beverly, MA) antibodies. Proteins were visualized using the ECL detection reagent from Amersham (GE Healthcare, UK).

DNA synthesis assay

BrdU (50 μg/kg body weight) (Sigma) dissolved in PBS with 7 mM NaOH was injected intraperitoneally into mice 6 h before sacrifice. After being fixed with 2% PFA and washed with 0.05% Tween 20 in PBS, liver frozen sections were treated with 2N HCl and neutralized in 0.1 M sodium tetraborate (pH 8.5). The sections were then stained with anti-BrdU antibody (BD Pharmingen, San Jose, CA) as described [52] using Alexa Fluor®488 goat anti-mouse IgG1 (Invitrogen, Carlsbad, CA) as a secondary antibody for visualization.

Statistical analysis

All data are presented as mean±SD. Scheffe’s F test and Bonferroni/Dunn correction were used to compare multiple groups of data. P<0.05 and P<0.01 were considered as statistically significant and great significant respectively.

Supporting Information

Figure S1 Mesenchymal—epithelial transition occurs in mouse liver development. Representative images of dual immunofluorescence of epithelial (ZO-1) and mesenchymal (vimentin) cells in C57BL/6J mice livers at different developmental stages. Scale bars = 100 μm. (TIF)

Figure S2 Hepatic stem cells are both epithelial- and mesenchymal-like. (A) Immunofluorescence of hepatocyte marker albumin, biliary cell marker CK7 and vimentin; (B) CK8/18, CK7 and vimentin; (C) E-cadherin, N-cadherin and vimentin; (D) E-cadherin, ZO-1 and vimentin expression in isolated c-Kit+CD49f+lowCD29+CD29−CD45−Ter119− hepatic stem cells with flow cytometry. Scale bars = 50 μm. (TIF)

Figure S3 Mesenchymal—epithelial transition occurs in stem cell-derived colonies during culture. (A) During culture day 1 to day 21, stem cells and stem cell-derived colonies were immunostained with albumin, CK7 and vimentin; (B) CK8/18, CK7 and vimentin; or (C) E-cadherin, ZO-1 and vimentin. (D) Partially differentiated stem cell colonies were indicated. Arrowhead, albumin and CK7 co-expressing cells. Scale bars = 100 μm. (TIF)

Table S1 List of Antibodies. 1st and 2nd antibodies used in the immunofluorescence experiments are listed. (DOC)

Table S2 List of TaqMan probes. TaqMan probes used for detection of the relative gene expressions are listed. (DOC)

Acknowledgments

The authors thank Atsushi Tanaka and Hideaki Sato for FACS operation, Dr. Masaki Kimura for western blot assistance.

Author Contributions

Conceived and designed the experiments: BL YZ HT. Performed the experiments: BL YZ YS. Analyzed the data: BL YZ YS. Contributed reagents/materials/analysis tools: BL YZ YS. Wrote the paper: BL YZ.

References

1. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. The Journal of clinical investigation 119: 1420.
2. Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265–273.
3. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704–715.
4. Polo JM, Hochedinger K (2010) When Fibroblasts MET iPSCs. Cell Stem Cell 7: 5–6.
5. Li R, Liang J, Ni S, Zhou T, Qiong X, et al. (2010) A Mesenchymal-to-Epithelial Transition Initiates and Is Required for the Nuclear Reprogramming of Mouse Fibroblasts. Cell Stem Cell 7: 51–63.
6. Samavarchi-Tehrani P, Golipour A, David L, Sung H, Beyer TA, et al. (2010) Functional Genomics Reveals a BMP-Driven Mesenchymal-to-Epithelial Transition in the Initiation of Somatic Cell Reprogramming. Cell Stem Cell 7: 64–77.
7. Yovchev MI, Grezdanov PN, Zhou H, Racherla H, Guha C, et al. (2008) Identification of adult hepatic progenitor cells capable of repopulating injured rat liver. Hepatology 47: 636–647.
8. Nitta T, Kim JS, Mhouczy D, Behrens KE (2008) Murine cirrhosis induces hepatocyte epithelial mesenchymal transition and alterations in survival signaling pathways. Hepatology 48: 909–919.
9. Omenetti A, Porrello A, Jung Y, Yang L, Popov Y, et al. (2008) Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest 118: 3331–3342.
10. Choi SS, Diehl AM (2009) Epithelial-to-mesenchymal transitions in the liver. Hepatology 50: 2007–2013.
11. Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, et al. (2007) Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 282: 23337–23347.
12. Godoy P, Hengsberger JG, Illeku I, Meyer C, Bachmann A, et al. (2009) Extracellular matrix modulates sensitivity of hepatocytes to fibroblastoid...
33. Kong D, Zhang Y, Matsuzaki Y (2007) Liver fibrosis: possible involvement of EMT. Cells Tissues Organs 185: 213–221.

34. Park MY, Kang KR, Park HS, Park BH, Choi HN, et al. (2007) Expression of the response factor in hepatocellular carcinoma: implications for epithelial-mesenchymal transition. Int J Oncol 31: 1309–1315.

35. Tommasi S, Pinto R, Platou B, Paradiso A (2007) Molecular pathways and related target therapies in liver carcinoma. Curr Pharm Des 13: 3279–3287.

36. Arias AM (2001) Epithelial mesenchymal interactions in cancer and development. Cell 105: 425–431.

37. Thiery JP, Acsoglu H, Huang RJ, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139: 871–890.

38. Gershengorn MC, Hardikar AA, Wei C, Geras-Raaka E, Marcus-Samuels R, et al. (2004) Epithelial-to-mesenchymal transition generates proliferative human adult precursor cells. Science 306: 2261–2264.

39. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nature Reviews Cancer 2: 442–454.

40. Stenger AM, Gerre MJ, Andreas I, Cama A, Galica F, et al. (1992) Expression of histone H3 cell cycle-related gene, vimentin and MYC genes in pediatric brain tumors. A preliminary analysis showing the different malignant cell growth potential. Molecular Brain Research 13: 273–275.

41. Lang SH, Hyde C, Reid IN, Hitchcock IS, Hart CA, et al. (2002) Enhanced expression of vimentin in mouse prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. The Prostate 52: 253–263.

42. Mendez MG, Kojima SI, Goldman RD (1838) Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. The FASEB Journal 24: 1838.

43. Erkes B, Coacci-Guyon E, Smola H, Nodder S, Babinet C, et al. (2000) Impaired wound healing in embryonic and adult mice lacking vimentin. J Cell Sci 113 Pt 13: 2453–2462.

44. Suzuki A, Zheng YW, Kaneko S, Onodera M, Fukao K, et al. (2002) Clonal cell lineages from islet progenitor cells in normal and diabetes-prone mouse. The FASEB Journal 16: 1772–1783.

45. Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nature Reviews Molecular Cell Biology 7: 131–142.

46. Spaderna S, Schmalhofer O, Hlubek F, Jung A, Kirchner T, et al. (2007) Epithelial-mesenchymal and mesenchymal-epithelial transitions during cancer progression. Verh Dtsch Ges Pathol 91: 21–28.

47. Hugo H, Ackland ML, Bick T, Lawrence MG, Clements JA, et al. (2007) Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 213: 374–383.

48. Herrmann H, Strelkov SV, Burkhard P, Arbi U (2009) Intermediate filaments: primary determinants of cell architecture and plasticity. J Clin Invest 119: 1772–1783.

49. Herrmann H, Sperlak SV, Burkhard P, Arbi U (2009) Intermediate filaments: primary determinants of cell architecture and plasticity. J Clin Invest 119: 1772–1783.

50. Gessler G, Ackland ML, Bick T, Lawrence MG, Clements JA, et al. (2007) Epithelial-mesenchymal and mesenchymal-epithelial transitions during cancer progression. Verh Dtsch Ges Pathol 91: 21–28.

51. Thiery JP, Sleeman JP (2006) Complex networks orchestrate epithelial-mesenchymal transitions. Nature Reviews Molecular Cell Biology 7: 131–142.

52. Morel AP, Lievre M, Thomas C, Hinkal G, Anselou S, et al. (2005) Growth of human breast cancer cells through epithelial-mesenchymal transition. PLoS ONE 3: e2888.

53. Baum B, Settleman J, Quinlan MP (2008) Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol 19: 294–306.

54. Wang N, Stanescovic D (2002) Mechanisms of vimentin intermediate filaments. Journal of muscle research and cell motility 23: 535–540.

55. Wang N, Stanescovic D (2000) Contribution of intermediate filaments to cell stiffness, stiffness, and growth. American Journal of Physiology- Cell Physiology 279: C1198.

56. Lanab G, Zhu QS, Huang KL, Wang S, Biskakovs N, et al. (2010) Vimentin Is a Novel Anti-Cancer Therapeutic Target; Insights from In Vitro and In Vivo Mice Xenograft Studies. PLoS ONE 5: e10105.

57. Venetianer A, Schiller DL, Magin T, Franke WW (1983) Cessation of cytokeratin expression in a rat hepatoma cell line lacking differentiated functions. Nature 305: 730–733.

58. Hiedberg KK, Chen LB (1986) Absence of intermediate filaments in a human gastric carcinoma-derived cell line. Experimental cell research 163: 369–377.

59. Lane EB, Hogan B, Kurkinen M, Garrels JJ (1983) Coexpression of vimentin and cytokeratin in parietal endoderm cells of early mouse embryo. Nature 303: 701–704.

60. Franke WW, Grun D, Kuhn C, Jackson BW, Illnerauer K (1982) Formation of cytoskeletal elements during mouse embryogenesis. III. Primary mesenchymal cells and the first appearance of vimentin filaments. Differentiation 23: 43–59.

61. Otsolo AS, Wald EA, Ramauer VP, Salas PJ (2007) Intermediate filament: a role in epithelial polarity. Experimental cell research 313: 2255–2264.

62. Nieminen M, Henriksen T, Martinen M, Marttila-Ichihara F, Eriksson JE, et al. (2006) Vimentin function in lymphocyte adhesion and transcellular migration. Nature cell biology 8: 156–162.

63. Tsoolo AS, Wald EA, Ramauer VP, Salas PJ (2007) Intermediate filament: a role in epithelial polarity. Experimental cell research 313: 2255–2264.

64. Juris JJ, Corbett J, Lancer J, Ellis GL, Ruben A, et al. (2007) Role of intermediate filaments in mouse embryonic development. Developmental Dynamics 236: 2792–2798.

65. von der Emde PL (2005) Intermediate filaments: primary determinants of cell architecture and plasticity. J Clin Invest 119: 1772–1783.

66. Herrmann H, Strelok SV, Burkhard P, Arbi U (2009) Intermediate filaments: primary determinants of cell architecture and plasticity. J Clin Invest 119: 1772–1783.

67. Morel AP, Lievre M, Thomas C, Hinkal G, Anselou S, et al. (2005) Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 3: e2888.

68. Goldring K, Partridge T, Watt D (2002) Muscle stem cells. The Journal of pathology 197: 457–467.

69. Price J, Williams BP (2001) Neural stem cells. Current Opinion in Neurobiology 11: 564–567.

70. Gage FH (2000) Mammalian neural stem cells. Science 287: 1433.

71. Nakaya Y, Sheng G (2001) Expression of vimentin during gastrulation: an embryological view. Development, Growth & Differentiation 49: 735–766.

72. Brabletz S, Schmalhofer O, Brabletz T (2009) Gastrointestinal stem cells in development and cancer. J Pathol 217: 307–317.

73. Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, et al. Epithelial to Mesenchymal Transition Is Mechanistically Linked with Stem Cell Signatures in Prostate Cancer Cells. PLoS ONE 5: e12445.